Showing results (291-300 of 824) with videos related to
Sort By:
Pageof 83
Clinical Pharmacology : Advances and Applications|August 26, 2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and SelinexorNisha S Joseph, Yu-Tzu Tai, Kenneth C Anderson, et al.Seminars in Oncology|April 30, 2003
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasiasConstantine S Mitsiades, Nicholas Mitsiades, Steven P Treon, et al.Best Practice & Research. Clinical Haematology|July 20, 2005
Novel biological therapies for the treatment of multiple myelomaPaul G Richardson, Constantine S Mitsiades, Teru Hideshima, et al.Blood|April 20, 2004
Advances in biology of multiple myeloma: clinical applicationsTeru Hideshima, P Leif Bergsagel, W Michael Kuehl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Proteasome inhibition as a novel therapeutic target in human cancerS Vincent Rajkumar, Paul G Richardson, Teru Hideshima, et al.Leukemia & Lymphoma|May 3, 2008
Thalidomide and lenalidomide: Mechanism-based potential drug combinationsSonia Vallet, Antonio Palumbo, Noopur Raje, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Individualizing treatment of patients with myeloma in the era of novel agentsJesús San-Miguel, Jean-Luc Harousseau, Douglas Joshua, et al.British Journal of Haematology|September 10, 2011
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disordersJooeun Bae, Yu-Tzu Tai, Kenneth C Anderson, et al.Nature Reviews. Clinical Oncology|November 26, 2014
Current treatment landscape for relapsed and/or refractory multiple myelomaMeletios A Dimopoulos, Paul G Richardson, Philippe Moreau, et al.Cancers|December 10, 2021
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple MyelomaShih-Feng Cho, Lijie Xing, Kenneth C Anderson, et al.Pageof 83